FR3113237B1 - Produit pour le traitement de maladies virales par voie nasale - Google Patents

Produit pour le traitement de maladies virales par voie nasale Download PDF

Info

Publication number
FR3113237B1
FR3113237B1 FR2008276A FR2008276A FR3113237B1 FR 3113237 B1 FR3113237 B1 FR 3113237B1 FR 2008276 A FR2008276 A FR 2008276A FR 2008276 A FR2008276 A FR 2008276A FR 3113237 B1 FR3113237 B1 FR 3113237B1
Authority
FR
France
Prior art keywords
product
treatment
viral diseases
nasal
way
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2008276A
Other languages
English (en)
Other versions
FR3113237A1 (fr
Inventor
Stéphanie Audran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmosoft Fr
Original Assignee
Biopass SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopass SA filed Critical Biopass SA
Priority to FR2008276A priority Critical patent/FR3113237B1/fr
Priority to FR2010995A priority patent/FR3113249B1/fr
Priority to EP21755445.0A priority patent/EP4192424A1/fr
Priority to US18/040,468 priority patent/US20230330013A1/en
Priority to CA3188053A priority patent/CA3188053A1/fr
Priority to CN202180067905.9A priority patent/CN116249515A/zh
Priority to PCT/EP2021/071696 priority patent/WO2022029140A1/fr
Publication of FR3113237A1 publication Critical patent/FR3113237A1/fr
Application granted granted Critical
Publication of FR3113237B1 publication Critical patent/FR3113237B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

PRODUIT POUR LE TRAITEMENT DE MALADIES VIRALES PAR VOIE NASALE L’invention concerne un produit pour le traitement par voie nasale de maladies virales, comme le COVID-19. Le produit comprend un hydrogel comprenant du glycérol, un carbomère, et éventuellement un mucopolysaccharide.
FR2008276A 2020-08-04 2020-08-04 Produit pour le traitement de maladies virales par voie nasale Active FR3113237B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR2008276A FR3113237B1 (fr) 2020-08-04 2020-08-04 Produit pour le traitement de maladies virales par voie nasale
FR2010995A FR3113249B1 (fr) 2020-08-04 2020-10-27 Produit pour le traitement par voie nasale de maladies virales
US18/040,468 US20230330013A1 (en) 2020-08-04 2021-08-03 Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route
CA3188053A CA3188053A1 (fr) 2020-08-04 2021-08-03 Hydrogel comprenant du glycerol et un carbomere pour le traitement par voie nasale des symptomes respiratoires de la maladie covid-19
EP21755445.0A EP4192424A1 (fr) 2020-08-04 2021-08-03 Hydrogel comprenant du glycerol et un carbomere pour le traitement par voie nasale des symptomes respiratoires de la maladie covid-19
CN202180067905.9A CN116249515A (zh) 2020-08-04 2021-08-03 用于通过鼻腔途径治疗covid-19疾病的呼吸道症状的包含甘油和卡波姆的水凝胶
PCT/EP2021/071696 WO2022029140A1 (fr) 2020-08-04 2021-08-03 Hydrogel comprenant du glycerol et un carbomere pour le traitement par voie nasale des symptomes respiratoires de la maladie covid-19

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2008276A FR3113237B1 (fr) 2020-08-04 2020-08-04 Produit pour le traitement de maladies virales par voie nasale
FR2008276 2020-08-04

Publications (2)

Publication Number Publication Date
FR3113237A1 FR3113237A1 (fr) 2022-02-11
FR3113237B1 true FR3113237B1 (fr) 2023-06-09

Family

ID=73038196

Family Applications (2)

Application Number Title Priority Date Filing Date
FR2008276A Active FR3113237B1 (fr) 2020-08-04 2020-08-04 Produit pour le traitement de maladies virales par voie nasale
FR2010995A Active FR3113249B1 (fr) 2020-08-04 2020-10-27 Produit pour le traitement par voie nasale de maladies virales

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR2010995A Active FR3113249B1 (fr) 2020-08-04 2020-10-27 Produit pour le traitement par voie nasale de maladies virales

Country Status (1)

Country Link
FR (2) FR3113237B1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
FR2973701B1 (fr) * 2011-04-06 2013-10-04 Biopass S A Composition pour application topique
CA2992352C (fr) 2015-07-14 2023-06-27 Marinomed Biotech Ag Composition de deblocage de nez congestionne presentant une activite antivirale
CN106511321B (zh) * 2016-12-20 2019-03-29 四川省中医药科学院 具有抗炎/抗病毒作用的组合物及药物
CN110840826A (zh) * 2019-11-19 2020-02-28 长春呈实健康实业有限公司 一种鼻阻隔剂及其制备方法
CN111437270A (zh) * 2020-04-24 2020-07-24 瑞希(重庆)生物科技有限公司 一种卡拉胶鼻用即型凝胶喷雾剂及其制备方法
CN111544556A (zh) * 2020-05-07 2020-08-18 中国人民解放军军事科学院军事医学研究院 一种适用于病毒性感冒、病毒性肺炎的中药组合物及其给药方式和制备
CN111773150A (zh) * 2020-06-22 2020-10-16 复旦大学 一种抗covid-19免洗手凝胶及其制备方法

Also Published As

Publication number Publication date
FR3113237A1 (fr) 2022-02-11
FR3113249B1 (fr) 2024-01-19
FR3113249A1 (fr) 2022-02-11

Similar Documents

Publication Publication Date Title
MX2021007156A (es) Inhibidores de kif18a.
MX2022001181A (es) Inhibidores de kif18a.
EA201990019A1 (ru) Соединения и композиции для подавления активности shp2
MX2021007158A (es) Heteroarilamidas utiles como inhibidores de kif18a.
MX2021007157A (es) Heteroarilamidas utiles como inhibidores de kif18a.
HN2005000508A (es) Procesos para la preparacion de 2-(2,6-dixopiperidin-3-il)-1-oxoisoindolinas sustituidas
MX2022010952A (es) Compuestos para la degradacion dirigida de brd9.
EA201790889A1 (ru) Офтальмологический раствор
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
MX2021013671A (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
MX2021002380A (es) Conjugados de isoquinolina-esteroide y usos de los mismos.
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022001084A (es) Metodo de tratamiento de la enfermedad de alzheimer mediante la regulacion de microrganismos intestinales.
WO2021100029A3 (fr) Promédicaments de fulvestrant
FR3113237B1 (fr) Produit pour le traitement de maladies virales par voie nasale
IL279168B (en) A process for the preparation of eribulin
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
WO2020214100A3 (fr) Composition
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MA61742A1 (fr) Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation
WO2020183173A3 (fr) Rétinoïdes synthétiques destinés à être utilisés dans l'activation de rar

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220211

PLFP Fee payment

Year of fee payment: 3

RM Correction of a material error

Effective date: 20221104

TP Transmission of property

Owner name: COSMOSOFT, FR

Effective date: 20221206

PLFP Fee payment

Year of fee payment: 4